Add this topic to your myFT Digest for news straight to your inbox
People with signs of ‘amyloid plaques’ on the brain could be treated before they develop symptoms
Elsewhere, energy stocks enter the red as price of crude oil skids
Companies with drugs already in clinical testing are being evaluated
US pharma group to shed 11% of workforce and pledges $250m of savings a year in restructure
Group aims to win green light for first treatment for the disease since 2003
Hillary Clinton comments on ‘price-gouging’ hit the sector — but it was already vulnerable
Biogen slide after lower full-year forecast weighs on biotechs
If inflation is gone forever, it’s hard to overpay for future growth
The market’s view on the impact of biosimilars is sanguine, but this may be wrong
But strong dollar hurts results because of effect on value of European sales
US biotech group’s shares rise 7% after experimental treatment slows rate of cognitive decline
Venture capital fund backed by UK ministers and drug companies
Drugs pipeline improves but report finds biological treatments are beginning to face competition
Company’s fourth-quarter profits nearly double on MS drug sales
Advances in innovation help sector add to 2014 gains, bucking wider January sell-off
Roche, J&J and Biogen in series of tie-ups a day after Shire deal to buy NPS
Exposure to oil price accounts for about 12% of company’s revenues
US stocks shake off decline after global rally
US stocks fall modestly after S&P 500’s biggest rally of year
The trick is in seeing where the overvaluation lies
Group’s valuation rests on select band of experimental drugs
Simplification is good but the units face the same challenges
International Edition